The heightened scrutiny of GLP-1 therapy

Published: 21-May-2026

GLP-1 therapies are creating demand for precision-engineered companion nutrition products that are tailored to the altered physiologies of their users, reports Aaron Quinn, Head of Business Development, Europe, at Vantage Nutrition

You need to be a subscriber to read this article.
Click here to find out more.

The rapid emergence of GLP-1 receptor agonists into obesity management is fundamentally reshaping the metabolic health landscape.

In major clinical trials, Semaglutide has demonstrated average weight losses of approximately 15%, while higher doses of Tirzepatide have approached 20%.1

With millions of individuals now using GLP-1 therapies globally, and forecasts projecting continued growth through 2030 and beyond, the implications for other health categories are significant.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.

Subscribe now Already a subscriber? Sign in here.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like